By profiling the proteome of 206 gastric tumor samples, Li et al. revealed that patients with high T-cell receptor signaling respond to anti-HER2-based therapy, whereas activation of the extracellular matrix/PI3K-AKT pathway impairs the anti-tumor effect of trastuzumab [106]. The gene discussed is AKT1; the disease is neoplasm.